SCG-Stockholm - A Swedish node within the Structural Genomics Consortia
- Reference number
- A3 04:164
- Start and end dates
- 040101-091231
- Amount granted
- 39 000 000 SEK
- Administrative organization
- Karolinska Institutet
- Research area
- Life Sciences
Summary
The Structural Genomics Consortium (SGC) is a not-for-profit organization that aims to determine the three dimensional structures of proteins of medical relevance, and place them in the public domain without restriction. The initiative was launched in Oxford and Toronto in April 2003 with funding from Canadian and British sponsors from both the public and private sectors (The Wellcome Trust, GlaxoSmithKline, Genome Canada, the Ontario Research and Development Challenge Fund, the Ontario Innovation Trust and the Canadian Institutes of Health Research). In 2005, a consortium of Swedish sponsors (VINNOVA, SSF, KAW and KI) provided funds to the SGC and a Swedish node was launched at the Karolinska Institutet. The goal of the SGC is to develop the infrastructure and technologies necessary for rapid, parallel structure determination, with the aim of having the capability to determine more than 200 protein structures per year. Over the first three years, the SGC is targeting 400 proteins that have relevance to human health and disease, such as proteins associated with diabetes, cancer, and infectious diseases such as malaria. Targets are also chosen based on interest from the academic and pharmaceutical communities, expertise within the Consortium and scientific impact. The Consortium operates out of the University of Toronto, University of Oxford and Karolinska Institutet, Stockholm. The Toronto and Oxford laboratories have been functional since mid-2004, the Stockholm laboratory, hosted by the Department of Medical Biochemistry and Biophysics, became operational in April 2005.